
Rajat Bannerji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2763851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 2022, 6, 1232-1242.	2.5	14
2	Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematology,the, 2022, 9, e327-e339.	2.2	98
3	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2021, 16, 72-81.	1.2	7
4	Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e890-e896.	0.2	6
5	Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (RECN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance. Blood, 2020, 136, 10-11.	0.6	20
6	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood, 2019, 134, 762-762.	0.6	50
7	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemotherapy and Pharmacology, 2013, 72, 897-908.	1.1	73
8	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH) Tj ETQq0 0 0 2010, 116, 3966-3966.) rgBT /Ov 0.6	erlock 10 Tf 5 6
Q	Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis	0.6	13

971-971.